ILC Therapeutics

ILC Therapeutics completes £2.5m financing and bolsters C-suite

Owain Millington appointed CEO, Julie Bailey appointed CFO and Dawn Firmin appointed COO Financing to support pre-clinical development of ILCT’s two lead assets 11 September 2024 -- Glasgow, UK -- ILC Therapeutics, a specialist developer of hybrid interferons, a new drug class engineered for improved therapeutic profiles across multiple indications, announces that it has successfully...
75 King William Street London EC4N 7BE

+4402079338780